ImmuPharma (LON:IMM) Stock Price Up 34.1% - Should You Buy?

Key Points

• ImmuPharma's stock price rose by 34.1%, reaching a high of GBX 11.50 ($0.16) during mid-day trading, with trading volume increasing significantly from its average.
• The company's market capitalization stands at £54.02 million, with a negative PE ratio of -1,214.61 and a beta of 1.53, indicating high volatility.
• ImmuPharma is a specialty biopharmaceutical company focused on developing peptide-based therapeutics, with its lead program targeting autoimmune diseases like Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shares rose 34.1% during mid-day trading on Tuesday . The stock traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). Approximately 57,593,953 shares were traded during mid-day trading, an increase of 656% from the average daily volume of 7,620,919 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Stock Performance

The firm has a 50-day moving average price of GBX 2.55 and a 200-day moving average price of GBX 2.76. The stock has a market cap of £54.02 million, a PE ratio of -1,214.61 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.